Department of Internal Medicine- Nephrology & Transplantation, Erasmus MC Transplantation Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Sci Rep. 2021 Jun 14;11(1):12445. doi: 10.1038/s41598-021-91967-w.
Pre-transplant screening focuses on the detection of anti-HLA alloantibodies. Previous studies have shown that IFN-γ and IL-21 producing T cells are associated with the development of acute rejection (AR). The aim of this study, was to assess whether pre-transplant donor-reactive T cells and/or B cells are associated with increased rejection risk. Samples from 114 kidney transplant recipients (transplanted between 2010 and 2013) were obtained pre-transplantation. The number of donor-reactive IFN-γ and IL-21 producing cells was analyzed by ELISPOT assay. The presence of donor specific antibodies (DSA) was also determined before transplantation. Numbers of donor-reactive IFN-γ producing cells were similar in patients with or without AR whereas those of IL-21 producing cells were higher in patients with AR (p = 0.03). Significantly more patients with AR [6/30(20%)] had detectable DSA compared to patients without AR [5/84(5.9%), p = 0.03]. Multivariate logistic regression showed that donor age (OR 1.06), pre-transplant DSA (OR 5.61) and positive IL-21 ELISPOT assay (OR 2.77) were independent predictors of an increased risk for the development of AR. Aside from an advanced donor-age and pre-transplant DSA, also pre-transplant donor-reactive IL-21 producing cells are associated with the development of AR after transplantation.
移植前筛查侧重于检测抗 HLA 同种抗体。先前的研究表明,IFN-γ 和 IL-21 产生的 T 细胞与急性排斥反应(AR)的发展有关。本研究旨在评估移植前供体反应性 T 细胞和/或 B 细胞是否与增加的排斥风险相关。本研究共纳入 114 例肾移植受者(2010 年至 2013 年期间移植),在移植前采集样本。通过 ELISPOT 分析检测供体反应性 IFN-γ 和 IL-21 产生细胞的数量。在移植前还确定了供体特异性抗体(DSA)的存在。AR 患者和无 AR 患者的供体反应性 IFN-γ 产生细胞数量相似,而 AR 患者的 IL-21 产生细胞数量较高(p=0.03)。与无 AR 患者相比,AR 患者[6/30(20%)]中更多的患者存在可检测的 DSA(p=0.03)。多变量逻辑回归显示,供体年龄(OR 1.06)、移植前 DSA(OR 5.61)和阳性 IL-21 ELISPOT 检测(OR 2.77)是 AR 发展风险增加的独立预测因子。除了供体年龄较大和移植前 DSA 外,移植前供体反应性 IL-21 产生细胞也与移植后 AR 的发生有关。